GlobeNewswire by notified

Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia

Share

COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5’-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTIONIN AN AML MODEL

Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced the publication of a scientific abstract for an upcoming poster presentation at the 20th Cancer Immunotherapy (CIMT) Annual Meeting, being held from May 10-12, 2022. The abstract discloses new preclinical data on DCP-001, Immunicum’s lead clinical candidate, in combination with 5’-azacitidine (5-AZA), a hypomethylating agent, and venetoclax (VEN), a BCL2 inhibitor, in a preclinical setting. The in vivo and in vitro data support the evaluation of DCP-001 as a potential combination therapy with 5-AZA+VEN in acute myeloid leukemia (AML) and related hematological malignancies and demonstrated stronger tumor volume reduction in combination than either vaccination or drug treatment alone.

“The preclinical data that will be presented at the upcoming CIMT meeting provides a promising snapshot of the therapeutic potential of combining relapse vaccination using DCP-001 with a highly active treatment regimen especially for elderly AML patients. The use of DCP-001 in this setting could broaden the positioning of DCP-001 beyond the AML maintenance setting with a focus on supporting patients reaching complete response,” said Alex Karlsson-Parra, Chief Scientific Officer at Immunicum. “We expect to further build upon this preclinical data with updated clinical data from the ADVANCE II study in the near term, which evaluates DCP-001 as monotherapy in the AML maintenance setting. Together, these data sets will add to the growing body of data to further validate this program and its potential for the treatment of AML.”

DCP-001 is a cell-based cancer vaccine generated by differentiation and maturation of Immunicum’s proprietary human DCOne myeloid leukemic cell line into a mature dendritic cell phenotype. This results in a vaccine comprising a broad array of endogenous tumor-associated antigens combined with a mature dendritic cell costimulatory profile. Preclinical studies suggest that upon intradermal vaccination, DCP-001 is phagocytosed by local and recruited antigen-presenting cells (APC), resulting their activation and migration to the draining lymph nodes to (re)activate tumor-reactive T-cells. In clinical studies, intradermal DCP-001 vaccination has been shown to be safe and feasible as a post-remission therapy in AML. Importantly, immunomonitoring confirmed that DCP-001 vaccination resulted in anti-tumor immune responses that correlated with long-term survival.

To evaluate a potential combination of DCP-001 vaccination with 5-AZA + VEN in a preclinical setting, a humanized mouse model for AML was used. Mice were randomized and assigned to four groups: untreated control, vaccination alone, treatment with 5-AZA + VEN alone, and combination. The mean tumor volume 6 weeks after therapy initiation was significantly reduced in the combination group (181.8 ± 29 mm3) as compared to control (522 ± 97.5 mm3), but also vaccination (326.9 ± 54.6 mm3) or drug treatment alone (293.8 ± 29 mm3). Additional in vitro studies detected no negative impact of 5-AZA + VEN on the viability, recovery or phenotype of DCP-001. Moreover, no influence of either 5-AZA or VEN was observed on the ability of DCP-001 to stimulate proliferation of allogeneic peripheral blood lymphocytes or on the ability of allogeneic monocyte-derived immature dendritic cells to endocytose DCP-001-derived cellular content, a key component of the mechanism-of-action.


CIMT Presentation Details:

Abstract #38:         The cancer relapse vaccine DCP-001 acts synergistically with 5’-azacitidine / venetoclax treatment in a preclinical AML model

Presenter:        Satwinder Kaur Singh, PhD, Director Research at Immunicum AB

Session:         Therapeutic Vaccination

Date & Time:         Monday, 10 May 2022; 3:30-6:00 pm (CEST)

The full abstract is available on the CIMT website in the online program book and via the CIMT2022 app. For more information, please click here.


FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@immunicum.com


INVESTOR RELATIONS

Julie Seidel

Stern Investor Relations

Telephone: +1 212-362-1200

E-mail: julie.seidel@sternir.com


MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu


ABOUT IMMUNICUM AB (PUBL)

Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed28.5.2022 12:01:09 CEST | Press release

FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed Frontline Ltd. (“Frontline” or the "Company") (NYSE: FRO – OSE: FRO) announces that it has agreed to acquire a total of 5,955,705 shares in Euronav N.V. (NYSE: EURN & Euronext: EURN) (“Euronav”) representing 2.95% of the outstanding shares in privately negotiated share exchange transactions with certain shareholders of Euronav N.V. where such shareholders of Euronav N.V. receive consideration shares in Frontline. Frontline will issue a total of 8,337,986 new shares as a result of these transactions, equivalent to an exchange ratio of 1.4. Frontline will be entitled to the declared USD 0,06 dividend to be paid by Euronav on the acquired shares on 8 June 2022. Settlement is expected to take place on or about 1 June 2022 by delivery of existing shares through a share lending arrangement with Frontline's main shareholder Hemen Holding Ltd. Following completion of the issue of the new Frontline shares, F

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma28.5.2022 00:58:29 CEST | Press release

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1 Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indicati

ObsEva Announces Corporate Updates27.5.2022 22:01:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Am

CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.5.2022 16:20:00 CEST | Press release

Bid procedure, 2022-06-01BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: HEMSO FASTIGHETS AB: XS2173253407, 2025-05-13 HEMSO FASTIGHETS AB: XS2269194572, 2023-12-07 VASAKRONAN AB: SE0010599183, 2023-12-20 VASAKRONAN AB: XS2391917205, 2025-03-28 ESSITY AB: XS2355204608, 2025-01-17 SCANIA CV AB: XS2297918349, 2023-11-11 SCANIA CV AB: XS2382157571, 2024-09-02 ELECTROLUX AB: XS2152294679, 2023-04-06 ELECTROLUX AB: XS1969611943, 2024-03-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2022-04-27Bid date2022-06-01Bid times10.30-11.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS2173253407: 30 mln SEK +/-30 mln SEK XS2269194572: 30 mln SEK +/-30 mln SEK SE0010599183: 30 mln SEK +/-30 mln SEK XS2391917205: 30 mln SEK +/-

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.5.2022 16:20:00 CEST | Press release

Bid procedure, 2022-06-03BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2022-06-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 250 mln SEK +/-125 mln SEK 3114: 250 mln SEK +/-125 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 250 mln SEK per bid 3114: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-06-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-05-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be